This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Macular Degeneration  • Alert me on articles by topic  Social Bookmarking   What's this?

Arch Ophthalmol. 2003;121:1634-1636.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

IT HAS been 2 years since the October 2001 issue of Archives of Ophthalmology reported the main treatment outcomes of the Age-Related Eye Disease Study (AREDS).^1-2 The current issue of the ARCHIVES contains an analysis of the public health effects of AREDS³; it estimates the number of people in the United States who should benefit from the use of the AREDS supplement. The article calculates that 8 million people 55 years and older in the United States have monocular or binocular intermediate age-related macular degeneration (AMD) or monocular advanced AMD, which places them at considerable risk for progression to advanced AMD. In a 5-year period, 1.3 million of these people would be expected to develop advanced AMD if no treatment were given. If the AREDS formulation were used by these individuals, the authors calculate that approximately 329 000 patients would avoid advanced AMD and its visual loss during this 5-year . . . [Full Text of this Article]

Lee M. Jampol, MD
Chicago, Ill

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Beta Carotene Supplementation and Age-Related Maculopathy in a Randomized Trial of US Physicians
Christen et al.
Arch Ophthalmol 2007;125:333-339.
ABSTRACT | FULL TEXT